"Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including Biogen raising prices for some of its drugs according to Cowen. » Read More
Our traders are hearing that cash rich companies are ready to spend. Don't agree? Just take a look at some of the action that’s come down over the past few days!
Stocks ended higher Wednesday, led by financials as the sector got a shot of confidence from a well-known analyst -- and investors. Staples and telecoms were the biggest decliners.
Stocks continued to rise Wednesday, led by banks, amid a fresh vote of confidence for the sector.
U.S. stock index futures were flat to slightly higher Wednesday after Wall Street eked out a gain Tuesday and investors waiting for economic data on the housing sector and business inventories.
On the eve of the 10-year anniversary of the dot-com bubble bursting the stock stat mavens here at CNBC sliced and diced all sorts of data on share price performance since March 10, 2000.
Get calls on Google, Joy Global, Biogen Idec and more.
Warren Buffett eased the throttle on energy while Bill Ackman had less on Target. George Soros and John Paulson loaded up on financials, while Carl Icahn backed off on Yahoo but jumped into Take Two.
Stocks closed broadly higher on optimism that help was on the way for Greece to deal with its heavy debt burden.
Stocks staged a relief rally Wednesday amid talks of a bailout for Greece and positive earnings and sales news from some key Dow components.
U.S. stock index futures are pointing to a higher open Tuesday morning, a day after a last-hour selloff pushed the Dow to its first close below 10,000 since November, and the S&P 500 to a fresh three-month closing low as well.
What follows is a roundup of corporate earnings reports for Tuesday, Feb. 9.
Thirteen-grand a year. That's about how much Acorda Therapeutics says it'll charge for its newly approved drug Ampyra for multiple sclerosis.
Pfizer, the world's largest drugmaker, is scheduled to report fourth-quarter results before the opening bell on Wednesday, February 3. Here is a look at how Pfizer shares traded during the most recent earnings reports.
The Chairman and CEO of Alkermes had the chutzpah to get on Twitter yesterday. And he apparently isn’t just there to be a voyeur and to keep an eye on what’s being said in the biopharma Twitterverse. Pops has already sent out at least a couple of tweets.
I'm gonna avoid all the cliches about JPM being the Super Bowl of investment conferences or the grandaddy of them all. As of earlier this week, JPM says 6,500 people are expected to attend (down slightly from last year,) more than 330 public and private companies are presenting and more than 7,500 so-called one-on-one meetings between analysts/investors and execs have been scheduled. Plus, a whole bunch of other meetings take place on the down low all over the city.
Talk about a blow to the ego. The shares may have since succumbed to the downdraft in the overall stock market, but when trading opened this morning Biogen Idec shot up around two percent. Investors were reacting to the news that the company's longtime CEO, Jim Mullen, is calling it quits.
It has been over a month and a half since the US House of Representatives passed its version of health care reform and today, the Senate passed its bill. Now the two bills must be reconciled and the debate will continue to heat up. Here are the biggest S&P Health Care gainers and losers over the past 6 months.
Our whales aren’t massive sea creatures, so much as massive investors who are massively wealthy... and they’ve recently surfaced to reveal their top holdings.
This weekend, the US House of Representatives passed its version of health care reform and now awaits a version from the Senate. The debate has been heating up since earlier this summer when President Obama was pushing for legislation before the summer recess. Here are the biggest S&P Health Care gainers and losers over while the debate has waged on.
Stocks retreated Tuesday after several earnings reports beat expectations but economic numbers missed their targets. The Dow shed more than 50 points, or 0.5 percent, but still held above 10,000. The S&P and Nasdaq each lost about 0.6 percent.